COVID-19 and diabetes: What do we know so far?
Prakash GangadaranHimabindu PadinjarathilShri Hari Subhashri RajendranManasi P JogalekarChae Moon HongBaladhandapani AruchamyUma Maheswari RajendranSridharan GurunagarajanAnand KrishnanPrasanna RamaniKavimani SubramanianPublished in: Experimental biology and medicine (Maywood, N.J.) (2022)
Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.
Keyphrases
- coronavirus disease
- sars cov
- type diabetes
- poor prognosis
- respiratory syndrome coronavirus
- cardiovascular disease
- insulin resistance
- glycemic control
- long non coding rna
- cardiovascular events
- metabolic syndrome
- risk factors
- mental health
- emergency department
- early onset
- depressive symptoms
- skeletal muscle
- wound healing
- coronary artery disease
- weight loss